2023 World Conference on Lung Cancer (Posters)-P1.27. Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Bronchioloalveolar Carcinoma of the Lung

P1.27. Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Bronchioloalveolar Carcinoma of the Lung - PDF(Slides)

Back to course

Pdf Summary

This study examined the use of ipilimumab and nivolumab in the treatment of bronchioloalveolar carcinoma (BAC) of the lung. BAC is a rare cancer that typically has a poor response to chemotherapy. In this phase 2 clinical trial, eight patients with BAC were treated with ipilimumab and nivolumab. <br /><br />The study found that two patients achieved a partial response (PR), resulting in an objective response rate (ORR) of 25%. One patient had ongoing regression of the tumor after almost 46 months, while another had regression and progression-free survival (PFS) of 24 months. Two additional patients had stable disease (SD) and ongoing PFS of 1320 days and 355 days, respectively. <br /><br />Among the four patients who remained alive, PFS ranged from 355 to 1375 days. The clinical benefit rate (CBR), defined as no progression for at least 6 months, was 63% (5/8). The median PFS was 16 months, with a 6-month PFS of 62% and a 12-month PFS of 50%. The median overall survival (OS) was 32.2 months, with 6-month and 12-month OS rates of 88%. <br /><br />The most common adverse events observed were fatigue, maculo-papular rash, dry mouth, hypoalbuminemia, vomiting, and creatinine increase. Pulmonary toxicity was reported in some patients, including cough, pneumonitis, and dyspnea, although most adverse events were grade 1-2. Grade 3-4 adverse events occurred in 50% of patients, and two patients discontinued treatment due to adverse events. No grade 5 adverse events were reported. <br /><br />This study suggests that the combination of ipilimumab and nivolumab may be effective in treating BAC, with durable responses seen in some patients. Further studies are needed to determine response and resistance markers, as well as to investigate the potential benefits of this treatment in a larger group of BAC patients.

Asset Subtitle

Young Kwang Chae

Meta Tag

Speaker Young Kwang Chae

Topic Early-Stage NSCLC: Innovation & New Technology

Keywords

ipilimumab

nivolumab

bronchioloalveolar carcinoma

lung cancer

chemotherapy

clinical trial

partial response

progression-free survival

adverse events

treatment effectiveness